Literature DB >> 10204927

The assessment of appropriate indications for laminectomy.

F Porchet1, J P Vader, T Larequi-Lauber, M C Costanza, B Burnand, R W Dubois.   

Abstract

We have developed criteria to determine the appropriate indications for lumbar laminectomy, using the standard procedure developed at the RAND corporation and the University of California at Los Angeles (RAND-UCLA). A panel of five surgeons and four physicians individually assessed 1000 hypothetical cases of sciatica, back pain only, symptoms of spinal stenosis, spondylolisthesis, miscellaneous indications or the need for repeat laminectomy. For the first round each member of the panel used a scale ranging from 1 (extremely inappropriate) to 9 (extremely appropriate). After discussion and condensation of the results into three categories laminectomy was considered appropriate in 11% of the 1000 theoretical scenarios, equivocal in 26% and inappropriate in 63%. There was some variation between the six categories of malalignment, but full agreement in 64% of the hypothetical cases. We applied these criteria retrospectively to the records of 196 patients who had had surgical treatment for herniated discs in one Swiss University hospital. We found that 48% of the operations were for appropriate indications, 29% for equivocal reasons and that 23% were inappropriate. The RAND-UCLA method is a feasible, useful and coherent approach to the study of the indications for laminectomy and related procedures, providing a number of important insights. Our conclusions now require validation by carefully designed prospective clinical trials, such as those which are used for new medical techniques.

Entities:  

Mesh:

Year:  1999        PMID: 10204927     DOI: 10.1302/0301-620x.81b2.8871

Source DB:  PubMed          Journal:  J Bone Joint Surg Br        ISSN: 0301-620X


  8 in total

Review 1.  Development of appropriateness criteria for the surgical treatment of symptomatic lumbar degenerative spondylolisthesis (LDS).

Authors:  A F Mannion; V Pittet; F Steiger; J-P Vader; H-J Becker; F Porchet
Journal:  Eur Spine J       Date:  2014-04-24       Impact factor: 3.134

2.  Developing an Appropriateness Criteria for Knee MRI Using the Rand Appropriateness Method (RAM)-2013.

Authors:  Hossein Ebrahimipour; Seyedeh Zahra Mirfeizi; Ali Vafaee Najar; Amir Reza Kachooei; Amir Shahriar Ariamanesh; Reza Ganji; Habibollah Esmaeeli; Hedayat Salari; Marjan Vejdani
Journal:  Arch Bone Jt Surg       Date:  2014-03-15

3.  Developing criteria for cesarean section using the RAND appropriateness method.

Authors:  Rahim Ostovar; Arash Rashidian; Abolghasem Pourreza; Batool Hossein Rashidi; Sedigheh Hantooshzadeh; Hassan Eftekhar Ardebili; Mahmood Mahmoudi
Journal:  BMC Pregnancy Childbirth       Date:  2010-09-14       Impact factor: 3.007

4.  The Effect of Gabapentin Plus Celecoxib on Pain and Associated Complications After Laminectomy.

Authors:  Aminolah Vasigh; Molouk Jaafarpour; Javaher Khajavikhan; Ali Khani
Journal:  J Clin Diagn Res       Date:  2016-03-01

5.  The Effect of Sevoflurane Plus Propofol on Pain and Complications after Laminectomy: A Randomized Double Blind Clinical Trial.

Authors:  Aminolah Vasigh; Fatemeh Najafi; Molouk Jaafarpour; Javaher Khajavikhan; Ali Khani
Journal:  J Clin Diagn Res       Date:  2017-04-01

6.  Multiple operations on the same patient.

Authors:  Fred L Cohen; Gary W Roberts
Journal:  Surg Neurol Int       Date:  2012-07-17

7.  Developing Criteria for Lumbar Spine Magnetic Resonance Imaging (MRI) Using RAND Appropriateness Method (RAM).

Authors:  Ali Keshtkaran; Mohammad Hadi Bagheri; Rahim Ostovar; Hedayat Salari; Majid Reza Farokhi; Atefeh Esfandiari; Hossein Yousefimanesh
Journal:  Iran J Radiol       Date:  2012-09-17       Impact factor: 0.212

8.  Comparing Gabapentin and Celecoxib in Pain Management and Complications After Laminectomy: A Randomized Double-Blind Clinical Trial.

Authors:  Aminolah Vasigh; Fatemeh Najafi; Javaher Khajavikhan; Molouk Jaafarpour; Ali Khani
Journal:  Iran Red Crescent Med J       Date:  2016-02-28       Impact factor: 0.611

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.